<SEC-DOCUMENT>0001628280-24-023064.txt : 20240514
<SEC-HEADER>0001628280-24-023064.hdr.sgml : 20240514
<ACCEPTANCE-DATETIME>20240514080302
ACCESSION NUMBER:		0001628280-24-023064
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240514
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240514
DATE AS OF CHANGE:		20240514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ovid Therapeutics Inc.
		CENTRAL INDEX KEY:			0001636651
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				465270895
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38085
		FILM NUMBER:		24941511

	BUSINESS ADDRESS:	
		STREET 1:		441 NINTH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001
		BUSINESS PHONE:		212-776-4381

	MAIL ADDRESS:	
		STREET 1:		441 NINTH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ovid-20240513.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:06b5678e-d464-4441-afdc-d00904d19689,g:b5895d10-5201-42b5-99bd-0de375344bf1,d:b1398493eba645f6858be8d280481167-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ovid-20240513</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-17">0001636651</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-18">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ovid-20240513.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-08</xbrli:startDate><xbrli:endDate>2024-03-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib1398493eba645f6858be8d280481167_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> May&#160;14, 2024</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-2">OVID THERAPEUTICS INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"> (Exact name of Registrant as Specified in Its Charter) </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-3">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-4">001-38085</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-5">46-5270895</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">(State or Other Jurisdiction</span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">(IRS Employer</span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">441 Ninth Avenue, 14th Floor</span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">New York, New York</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-6">10001</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:40%">&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-7">646</ix:nonNumeric>-<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-8">661-7661</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-9">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-10">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-11">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-12">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:38.505%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.508%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-13">Common Stock, par value $0.001 per share</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-14">OVID</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-15">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-16">&#9744;</ix:nonNumeric> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#9744; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib1398493eba645f6858be8d280481167_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:29.52pt">Results of Operations and Financial Condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;14, 2024, Ovid Therapeutics Inc. (the &#8220;Company&#8221;) issued a press release announcing Business Update, First Quarter 2024 Financial Results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27.74pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></div><div id="ib1398493eba645f6858be8d280481167_10"></div><div style="-sec-extract:summary;margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:29.52pt">Financial Statements and Exhibits.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibit</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:77.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:105%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline" href="ovid2024q1ex991maintaingui.htm">Press Release, dated</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">May&#160;14, 2024</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib1398493eba645f6858be8d280481167_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:26.19pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">OVID THERAPEUTICS INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">By: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;/s/ Thomas M. Perone</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;</span></div></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Thomas M. Perone</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">General Counsel &amp; Corporate Secretary </span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: May&#160;14, 2024</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ovid2024q1ex991maintaingui.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="icec6514bd4084cc88c6ca09f86cbac71_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><img alt="ovid-therapeutics_logo750s.jpg" src="ovid-therapeutics_logo750s.jpg" style="height:182px;margin-bottom:5pt;vertical-align:text-bottom;width:386px"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results</font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:13.8pt">Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome&#59; topline data are anticipated in Takeda's H1 2024 fiscal year</font></div><div><font><br></font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:13.8pt">A Phase 1, double-blind, multiple-ascending dose trial evaluating OV888 (GV101) is complete&#59; topline safety data are expected in H1 2024</font></div><div><font><br></font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:13.8pt">Ovid expects to initiate a Phase 2 clinical program studying OV888 (GV101) in cerebral cavernous malformations in H2 2024</font></div><div><font><br></font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:14.5pt">Cash, cash equivalents and marketable securities were $90.3 million as of March&#160;31, 2024&#59; this capital is expected to support operations into H1 2026</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">NEW YORK, May&#160;14, 2024</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Ovid Therapeutics Inc. (Nasdaq&#58; OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, today reported business updates and financial results for the first</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">quarter ended March&#160;31, 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#34;This is an exhilarating period for Ovid. Our innovative programs are progressing through clinical trials and moving closer to addressing the significant unmet needs of individuals with developmental and epileptic encephalopathies,&#34; stated Jeremy Levin, D.Phil, MB BChir., Chairman and CEO of Ovid Therapeutics. &#34;Takeda has recently completed two critical Phase 3 studies of soticlestat for Dravet syndrome and Lennox-Gastaut syndrome, and we are eagerly anticipating the outcomes as soticlestat could herald a new class of anti-seizure medication. Our license agreement with Takeda provides us with significant potential near- and longer-term financial resources.&#34;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#34;Furthermore, our collaboration with Graviton Bioscience has proven to be highly fruitful. We are on the brink of receiving the Phase 1 findings for our ROCK2 inhibition program and are planning to launch our Phase 2 study later this year, targeting cerebral cavernous malformations,&#34; Dr. Levin continued.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Pipeline Updates</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Ovid pipeline programs are advancing on track. Multiple data and regulatory milestones are expected before year-end. These include&#58;</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.8pt">Soticlestat&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Takeda has completed two pivotal Phase 3 trials studying soticlestat as a treatment for Lennox Gastaut syndrome (LGS) and Dravet syndrome (DS). Topline data for both trials are anticipated in Takeda's H1 2024 fiscal year (which is by or before September 2024). Takeda anticipates regulatory filings for soticlestat in its fiscal year 2024 (by or before March 31, 2025).</font></div><div><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.75pt">2024 American Academy of Neurology (AAN) meeting&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Takeda presented seven poster presentations, which were originally presented at the 2023 American Epilepsy Society meeting.  These posters support soticlestat's anticipated profile and mechanism of action, as well as the unmet need that persists in LGS and DS. Highlights included&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">Soticlestat is a potential first-in-class anti-seizure medicine with a mechanism of action that inhibits cholesterol 24 hydroxylase, reducing extra-synaptic glutamate, neuronal hyperexcitability, and seizure susceptibility.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">Soticlestat's metabolism has been well characterized, reflecting minimal concern of drug-to-drug interactions.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">Physiologically based pharmacokinetic models predicted that soticlestat has no clinically significant drug-to-drug interactions.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:13.75pt">Financial interest&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Ovid co-developed soticlestat with Takeda through the completion of Phase 2 studies and subsequently sold its rights back to Takeda. Ovid retains significant financial interest in soticlestat. If soticlestat is approved and commercialized, Ovid is eligible to receive regulatory and commercial milestone payments of up to $660 million, as well as tiered, low double-digit royalties up to 20% on global net sales from Takeda. Of these potential future payments, Ovid sold a 13% interest to Ligand Pharmaceuticals for $30 million in October 2023. Ovid retains 87% of its interest in any milestone payments and royalties. Ovid has no ongoing obligations or costs associated with the development of soticlestat.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%;padding-left:13.8pt">OV888 (GV101)&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Ovid and its collaborator, Graviton Bioscience, have completed a Phase 1 multiple-ascending dose (MAD) study of OV888 (GV101), with topline safety data expected in H1 2024. No serious adverse events were observed in the Phase 1 study. OV888 (GV101) is a highly selective ROCK2 inhibitor for the potential treatment of cerebral cavernous malformations (CCM) and other rare neurological conditions. Ovid and Graviton expect to initiate a Phase 2 program evaluating the safety and efficacy of OV888 in H2 2024.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%;padding-left:13.8pt">OV329&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Ovid is advancing two development programs (oral and intravenous) for OV329, a next-generation GABA-aminotransferase inhibitor for the potential treatment of chronic and acute seizures. Both programs are anticipated to have milestones this year and supportive preclinical findings.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:107%">Oral formulation</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:13.75pt">An oral formulation of OV329 for the potential treatment of chronic seizures is being evaluated in a Phase 1 safety study, which includes surrogate biomarkers to measure target engagement and clinical efficacy. The single-ascending dose portion is complete and no safety signals were observed. The multiple-ascending dose study is ongoing and is applying magnetic resonance spectrometry and transcranial magnetic stimulation as biomarkers of efficacy. Data are expected from the Phase 1 study in late 2024, as are further preclinical data characterizing OV329's safety profile relative to vigabatrin.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:107%">Intravenous (IV) formulation</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:13.75pt">An IV formulation of OV329 for the potential treatment of acute seizures is on track for an anticipated IND application or an equivalent regulatory application by late 2024. Further preclinical data supporting OV329 for the treatment of status epilepticus are expected later this year.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%;padding-left:13.8pt">OV350 and portfolio of potassium chloride co-transporter 2 (KCC2) direct activators&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Ovid is on track to submit an IV formulation of OV350 for an IND by year-end 2024. OV350 is the first program emerging from Ovid&#8217;s novel portfolio of KCC2 direct activators. The Company believes several of its direct activators have the potential to treat multiple diseases, including psychiatric and anticonvulsant indications, thereby enabling possible partnering and co-development opportunities. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">General Corporate &#38; Business Updates</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%;padding-left:13.8pt">Financial runway&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> Ovid anticipates its cash runway will support operations and clinical development programs into H1 2026. During this time, Ovid anticipates several events for its current pipeline programs as well as clinical and regulatory results for soticlestat from Takeda. </font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%;padding-left:13.8pt">Research &#38; development strategy&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Ovid is focused on the development of novel, targeted small molecules that have the potential to be first-in-class or best-in-class neurotherapeutics. The mechanisms of action in Ovid&#8217;s pipeline programs address biological targets implicated in neuronal hyperexcitability, vascular, and inflammatory disorders in the brain. The broad therapeutic potential of these mechanisms may enable future development and partnering in a range of neurological conditions, including seizures, psychiatric conditions, neurovascular and neurodegenerative diseases.</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%;padding-left:13.8pt">Business development activities&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Ovid&#8217;s future business development efforts are focused on&#58; potential collaborations to advance development opportunities for its KCC2 portfolio in non-core indications&#59; and the exploration of commercial opportunities for some of its programs in territories outside the United States.</font></div><div><font><br></font></div><div id="icec6514bd4084cc88c6ca09f86cbac71_4"></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Quarter 2024 Financial Results</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:13.8pt">Cash, cash equivalents and marketable securities as of March&#160;31, 2024 totaled $90.3 million.</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:13.8pt">Revenue was $148,000 for the first quarter ended March&#160;31, 2024, as compared to $66,000 in the same period in 2023. Revenues were the result of royalty and licensing agreements.</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:13.8pt">Research and development expenses were $10.4 million for the first quarter ended March&#160;31, 2024, compared to $6.6 million in the same period in 2023. The increase is related to advancement of Ovid's clinical pipeline as described above, including the addition of the OV888 (GV101) Phase 1 MAD program and expanded OV329 clinical development activities.</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:13.8pt">General and administrative (G&#38;A) expenses were $7.2 million for the first quarter ended March&#160;31, 2024, as compared to $8.3 million for the same period in 2023, reflecting reductions of full time G&#38;A employees made in 2023.</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:13.8pt">Total operating expenses were $17.6 million for the first quarter ended March&#160;31, 2024, as compared to $15.0 million for the same period last year.</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:13.8pt">Ovid reported a net loss of $11.7 million, or basic and diluted net loss per share attributable to common stockholders of $0.17, for the first quarter of 2024, as compared to a net loss of $13.4 million, or basic and diluted net loss per share attributable to common stockholders of $0.19, for the same period in 2023.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="icec6514bd4084cc88c6ca09f86cbac71_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Ovid Therapeutics</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Ovid Therapeutics Inc. is a New York-based biopharmaceutical company that is dedicated to meaningfully improving the lives of people affected by epilepsies and brain conditions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. Ovid is developing&#58; OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders&#59; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures&#59; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. Ovid also maintains a significant financial interest in the future regulatory development and potential commercialization of soticlestat, which Takeda is responsible for advancing globally. Soticlestat is a cholesterol 24-hydroxylase inhibitor, which is currently in Phase 3 trials for DS and LGS. For more information about these and other Ovid research programs, please visit www.ovidrx.com.</font></div><div style="text-align:justify"><font><br></font></div><div id="icec6514bd4084cc88c6ca09f86cbac71_10"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This press release includes certain disclosures by Ovid that contain &#8220;forward-looking statements,&#8221; including, without limitation&#58; statements regarding the potential use and development of OV888 (GV101), OV329, OV350 and compounds from Ovid&#8217;s library of direct activators of KCC2&#59; the potential therapeutic opportunity of OV888 (GV101), OV329, OV350 and compounds from Ovid&#8217;s library of direct activators of KCC2&#59; the timing of data readout of topline safety data from Ovid&#8217;s Phase 1, double-blind, multiple-ascending dose trial evaluating OV888 (GV101)&#59; the timing of initiation of Ovid&#8217;s Phase 2 clinical program studying OV888 (GV101) in CCM&#59; the potential opportunity for soticlestat&#59; the timing and data readout of Takeda&#8217;s two pivotal Phase 3 trials evaluating soticlestat for DS and LGS&#59; Ovid&#8217;s expectations regarding the duration of its cash runway and the expectation that it will support the advancement of Ovid&#8217;s pipeline and Ovid's potential future business development opportunities. You can identify forward-looking statements because they contain words such as &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;hope,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potentially,&#8221;  and &#8220;will,&#8221; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid&#8217;s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid&#8217;s ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its technology or its business strategy, or risks related to Ovid&#8217;s ability to identify business development targets or strategic partners, to enter into strategic transactions on favorable terms, or to consummate and realize the benefits of any business development transactions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption &#8220;Risk Factors&#8221; in Ovid&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 8, 2024, and in future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="icec6514bd4084cc88c6ca09f86cbac71_13"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unaudited</font></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.296%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands, except share and per share data)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For The Three Months Ended<br>March 31, 2024</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For The Three Months Ended<br>March 31, 2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other revenue</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,397&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,615&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,168&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,344&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,565&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,958&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,417)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,892)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,536&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,694)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,356)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,694)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,356)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,716,929</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,490,704</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,716,929</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,490,704</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="icec6514bd4084cc88c6ca09f86cbac71_16"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Select Condensed Consolidated Balance Sheet Data</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unaudited</font></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(in thousands)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</font></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Cash, cash equivalents and marketable securities</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,259&#160;</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,834&#160;</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Working capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:105%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,267&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,123&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Total assets</font></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,613&#160;</font></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,027&#160;</font></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Total stockholder's equity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,279&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,797&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:105%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Working capital defined as current assets less current liabilities</font></div></td></tr></table></div><div id="icec6514bd4084cc88c6ca09f86cbac71_19"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contacts</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investor Relations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Garret Bonney</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IR&#64;ovidrx.com</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(617) 735-6093</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Media</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Raquel Cabo</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RCabo&#64;ovidrx.com</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(646) 647-6553</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ovid-20240513.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:06b5678e-d464-4441-afdc-d00904d19689,g:b5895d10-5201-42b5-99bd-0de375344bf1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ovid="http://www.ovidrx.com/20240513" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ovidrx.com/20240513">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20240513_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20240513_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.ovidrx.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ovid-20240513_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:06b5678e-d464-4441-afdc-d00904d19689,g:b5895d10-5201-42b5-99bd-0de375344bf1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_7a98afed-7abd-4f5d-9c48-71ed64c9a5b8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_e235d7b5-d4e3-4ddf-8069-40325002f895_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_4cb1b28b-1fa8-433f-94d8-1bebb2368837_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c05c7bc4-6548-45fa-97de-fe981cfdf984_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4db902c3-b0d2-4dd8-8a27-c8818de1cbf0_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_efa7a4b2-7720-4f12-a384-1df5c74de8dd_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_1d204867-988f-48f6-8c7f-d76bf5b7abdd_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_57ce31be-a96d-430d-9b40-6088bb18b358_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c9cf8ff7-d008-409c-9834-940d6e1e88c6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_63911fd5-6f37-469c-9aec-ad50371c6773_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_86be1c60-e70e-4ea8-a3a9-ffc9e2d4f865_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1c0f080e-25e6-4424-bd7f-31ed2fef7f37_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_6fe0d144-1b2f-4a1a-923f-a5841bff70a1_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_72dfaa1a-68fe-4e4d-8340-f526e8e7396e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e1f8c58f-3636-45c9-b29b-6d1b85c68eeb_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4d376109-f50c-497e-be13-b25e767313a4_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_25f01725-6195-45e6-9783-8482a578c42f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_dc341ce8-3d22-4e6d-ba15-76a65c5c1202_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_299f1328-052a-4055-8697-686fdadbf426_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_fe1c43a1-062d-4bcb-bff2-b11a365af7f8_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_73e69949-4ff9-497d-a114-dee6fad022e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_499a5793-0f86-4c2f-9bda-2b0ecfff104a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_91a6986e-5d70-4f93-9724-e92e548731aa_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ovid-20240513_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:06b5678e-d464-4441-afdc-d00904d19689,g:b5895d10-5201-42b5-99bd-0de375344bf1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ovidrx.com/role/Cover" xlink:type="simple" xlink:href="ovid-20240513.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_974e2b2c-64e1-468a-b4f9-a5d9139de51b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_DocumentType_974e2b2c-64e1-468a-b4f9-a5d9139de51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e8a985ff-6bd8-488c-8d36-ae8e3dfe63ef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_DocumentPeriodEndDate_e8a985ff-6bd8-488c-8d36-ae8e3dfe63ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e85fd235-c208-4f71-96ee-b3c685fa4654" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_EntityRegistrantName_e85fd235-c208-4f71-96ee-b3c685fa4654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8431d884-b838-40fb-8baf-92a59f9053fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8431d884-b838-40fb-8baf-92a59f9053fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_aa60e6d2-49db-426e-9db0-c149de920df6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_EntityFileNumber_aa60e6d2-49db-426e-9db0-c149de920df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_2123db52-4e89-420f-8c4f-c07a59ef5d1c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_EntityTaxIdentificationNumber_2123db52-4e89-420f-8c4f-c07a59ef5d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0c874f37-bd29-4cf9-964a-3f9487354201" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_EntityAddressAddressLine1_0c874f37-bd29-4cf9-964a-3f9487354201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_f4cf7c70-c9fe-4522-921a-0f36259bd727" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_EntityAddressAddressLine2_f4cf7c70-c9fe-4522-921a-0f36259bd727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0629cae0-e031-4f7d-903a-0d7b25dc547b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_EntityAddressCityOrTown_0629cae0-e031-4f7d-903a-0d7b25dc547b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_167a954c-f7f3-422a-861c-986fcd475b7f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_EntityAddressStateOrProvince_167a954c-f7f3-422a-861c-986fcd475b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_059f6aed-fa03-4141-9c41-ebceda5a48dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_EntityAddressPostalZipCode_059f6aed-fa03-4141-9c41-ebceda5a48dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b53f0eb0-1460-4f34-8087-fbdba88aa05c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_CityAreaCode_b53f0eb0-1460-4f34-8087-fbdba88aa05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4d258e54-323a-4f57-8cdf-6815b5dc2058" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_LocalPhoneNumber_4d258e54-323a-4f57-8cdf-6815b5dc2058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_77b64f06-0037-49e7-84e1-272101a90dcd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_WrittenCommunications_77b64f06-0037-49e7-84e1-272101a90dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_4bce452d-f060-4c33-8c28-365da5168a0d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_SolicitingMaterial_4bce452d-f060-4c33-8c28-365da5168a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_4dee56dd-c164-4934-8445-b75827ad1a8b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_PreCommencementTenderOffer_4dee56dd-c164-4934-8445-b75827ad1a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_7940c6a5-f376-4189-aa7b-c87c16269133" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_7940c6a5-f376-4189-aa7b-c87c16269133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3164d514-bdcd-4f10-8ebd-ec04cd2f8140" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_Security12bTitle_3164d514-bdcd-4f10-8ebd-ec04cd2f8140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_69321820-e808-49f5-a8b5-9e45d482316d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_TradingSymbol_69321820-e808-49f5-a8b5-9e45d482316d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_25df5dfc-93d7-4bc7-ab33-c858425aae9b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_SecurityExchangeName_25df5dfc-93d7-4bc7-ab33-c858425aae9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b0b17fb1-b30d-4011-96a8-1be41cbf4906" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_EntityEmergingGrowthCompany_b0b17fb1-b30d-4011-96a8-1be41cbf4906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_81fefa56-6065-4c83-a620-5d140618eb8e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_EntityCentralIndexKey_81fefa56-6065-4c83-a620-5d140618eb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a1b48ad6-ca12-4a47-8282-cba05f7ba430" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca2ff1e-4791-479e-b7b9-e49c5855679a" xlink:to="loc_dei_AmendmentFlag_a1b48ad6-ca12-4a47-8282-cba05f7ba430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ovid-therapeutics_logo750s.jpg
<TEXT>
begin 644 ovid-therapeutics_logo750s.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X0""17AI9@  34T *@    @  8=I  0
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
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MR/M[3?$&C:H0-,U;3[PGH+>Y23/Y$UIU^>>I:-JNE-_Q,]-OK(@_\O$#Q_S
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MM7N-QDO)RZJ>2J]$7\% 'X5Z.74%4J<TMD)FW\*/ 5WX]\1K9QEH=/@Q)>7
M'W$[ ?[1Y _$]J^U?#^BZ?X>TBWTS2+9+:S@7:B+^I)[D]R>M<W\(?!\?@SP
M396+(!?S*)[QNYE8<CZ*,+^&>]=K6>-Q3K3LOA0(Y_QS?FQT&41G$DY\I3Z
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MGXV:G9ZS\3-7U'3)TN+.Y6"2*1>C P1_D>Q'8UPU>KATU2BGV7Y"/K3]D_\
MY)Q??]A23_T5%7M%>+_LG_\ ).+[_L*2?^BHJ]HKYS&?QY>I2"BBBN8 HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&VD6#_OI!_I#J?NJ?X?J>_M]:Q/A#X!N?'GB5;8[X]+M\27DZC[J]E!_O-C
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M^Q/V:?$']L?#>*SE?=<:7*ULP)YV'YD/TP2O_ :]5N)H[>"2:9@D4:EW8]%
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M%_V3_P#DG%]_V%)/_145>T5\YC/X\O4I!1117, 4444 %%%% !1110 4444
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M_O1(6KQ*^E\^]N)1_P M)&;\SFO6/$%Z+'1[J?.&"%5_WCP/YUY_X#T=M?\
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MBBB@ (!&",@U\C_'#X2W?AG4+C6M!MVFT"9C(Z1C)M">H(_N>A[=#V)^N*&
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MBB@ HK&\97VHZ;X7U*\T.T^V:E#$6@@V,_F-Z;5()_"O$/\ A9?Q>_Z$9?\
MP6W'_P 76]+#RJJ\6OO ^B**^9]:^,OQ+T.V2XUGPM9V$#OY:R7%E/&K-@G
M)?K@'\JMVOQ3^+%W:Q7-KX+BFMYD$D<B:?<%74C((._D$5M]0J6O=?>*Y]&T
M5X%I'Q%^*UQJME#>>"UBM9)T263^SK@;$+ ,<E\# S7I_P 7&9/AEXE9"586
M,A!!P1Q64L/*$E&36OS&==17DW[,4CR_#!6E=G;[;,,L<G^&O6:SJT_9S<.P
M!11168!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%0WMU#8V<]W=R+%;P1M+)(W1549)/T H FHK+\.^(-*\263WFAWL5
M[;)(8FDCS@, "1S[$?G6I3:<79@%%>*:Q\1?%%K\=K;PO!9QMI#RQ1>7Y)+O
M&R@M+N_V<D^F%P:]KK2I2E32<NJN 4445D 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M (9M\/?]!G5O_(?_ ,36<(X>$E)3>GD!T/[--V]U\*+&-R3]FGFA7/IO+?\
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M?A!XM\#W4NJ?#77)YD'S-:,P21@.Q'W)/Q ]A76W2Q*7,^67X/\ R$>P^./
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M2H8U)1NOOV(Y((YXG#QC*A-2=M4!];U\^_M8:PDUIH7ANV/FWDUQ]K:->2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
' "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139734377409840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OVID THERAPEUTICS INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-5270895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">661-7661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OVID<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001636651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M$TL>-QO'AA9Y^8._$1JV"^5E#!LT)LT+\#P20K\WS)ZAVO*-_P502P,$%
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " !@0*Y8F5R<(Q &  "<)P  $P
M            @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M &! KEB*/-R$UP,  /X-   8              " @0T(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " !@0*Y8GZ ;\+$"  #B#   #0
M            @ $:#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( &! KEB7
MBKL<P    !,"   +              "  ?8.  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( &! KEBJQ"(6,P$  "("   /              "  =\/  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " !@0*Y8)!Z;HJT   #X 0  &@
M        @ $_$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " !@0*Y899!YDAD!  #/ P  $P              @ $D$@  6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  !N$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>18</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ovid-20240513.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-60520-DocumentPeriodEndDate-Missing] Submission type 8-K should have a non-empty value for DocumentPeriodEndDate in the Required Context. ovid-20240513.htm </Log>
    <Log type="Warning">[dq-60548-EntityAddressAddressLine1-Missing] Submission type 8-K should have a non-empty value for EntityAddressAddressLine1 in the Required Context. ovid-20240513.htm </Log>
    <Log type="Warning">[dq-60548-EntityAddressCityOrTown-Missing] Submission type 8-K should have a non-empty value for EntityAddressCityOrTown in the Required Context. ovid-20240513.htm </Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="ovid-20240513.htm">ovid-20240513.htm</File>
    <File>ovid-20240513.xsd</File>
    <File>ovid-20240513_lab.xml</File>
    <File>ovid-20240513_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="18">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ovid-20240513.htm": {
   "nsprefix": "ovid",
   "nsuri": "http://www.ovidrx.com/20240513",
   "dts": {
    "inline": {
     "local": [
      "ovid-20240513.htm"
     ]
    },
    "schema": {
     "local": [
      "ovid-20240513.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ovid-20240513_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ovid-20240513_pre.xml"
     ]
    }
   },
   "keyStandard": 18,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2022": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 18
   },
   "report": {
    "R1": {
     "role": "http://www.ovidrx.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ovid-20240513.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ovid-20240513.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001628280-24-023064-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-023064-xbrl.zip
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M;C+_6'79X"SG&D#<@(YP),8;%P%,-VD!=(+Z[<!CXY_9)$>X=Y8;&'8UU[2
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M#6/]03^%P Y7".9B.%R#@2NV487_K9V,WM.UZ82*G$>1#XP//+7_J?2C#Z$
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MWGBW]M_/]L\*]DN]G#P!4$L#!!0    ( &! KE@*0@H 0PH  !18   5
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MOL2CWY!XI%L1_Q]N0G2[_=#EQL/-=^+</#I]M7XF6_X1V=-7_P-02P,$%
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M1>;,N-+RZ[*'D6+"G<H=P3HM<IQL-E>0/[>EL)(&[11)HM"8[1I+G"L\":9
MZ[BV3(A=4N2)!L.(,N&NY4XA?NV  N$*@^(=X_Z\;"M8"F1X5$P2CU$/4R-&
MB0$?"00J0^3),$G'A9,O) ZCPX1[E:,@?&7WGV?7O<7XZ6[MFVJIK>#,<$K
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M)1AOBUZ_@<U^3F,,Z@Q5#(B#LP$"PI!WE3%C#*S> ?)E I]>2Z5]B41,=(5
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MDLYXD@A"9A>#)HN0X+5 6PYT"EI,]FMK"3%#ZQ0R4R#,P1S&&$%^+U L&G,
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M%2)3#&C..#^]XAI)0@WL#D P[6I\B69"TOPFI%[(\,ZDA@K!\[RA, MI%Y+
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MJS>GRB?-@ XCJP$2.L=I(2%5(C[GSV'\#:Q_6-H. W06O2*B06?>,\E16,X
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MKWUK]0:1:ZM]R-JM3J5]=+287#?CG=@_=E4P@3^#9!B^^G]02P$"% ,4
M" !@0*Y8N]"0Y(\/  "-<P  $0              @ $     ;W9I9"TR,#(T
M,#4Q,RYH=&U02P$"% ,4    " !@0*Y8E\!/0VH"  !J!P  $0
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A=&%I;F=U:2YH=&U02P4&      4 !0!0 0  TT

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>ovid-20240513_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ovid-20240513.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2024-03-08</startDate>
            <endDate>2024-03-08</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-17">0001636651</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-18">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="c-1" id="f-2">OVID THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-4">001-38085</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-5">46-5270895</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-6">10001</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-7">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-8">661-7661</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-9">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-10">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-11">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-12">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-13">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-14">OVID</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-15">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-16">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
